

# Hodgkin Lymphoma Pathways

---

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_

Stage: \_\_\_\_\_

Line of Therapy: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_

## First Line of Therapy (1<sup>st</sup> Line)

- Stages IA-IIB\* (Early Stage)
  - Classical Hodgkin's Lymphoma, Favorable and Unfavorable Risk
    - ABVD**: doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT<sup>†</sup>
- Stages IIIA-IVB\* (Advanced Stage)
  - Classical Hodgkin's Lymphoma
    - ABVD**: doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT<sup>†</sup>
    - A-AVD**: brentuximab vedotin, doxorubicin (Adriamycin), vinblastine, and dacarbazine

---

\* With or without extranodal disease

† ISRT – Involved site radiation therapy

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.